Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.

JMIR research protocols

van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW.
PMID: 28705789
JMIR Res Protoc. 2017 Jul 13;6(7):e136. doi: 10.2196/resprot.7790.

BACKGROUND: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; median survival is 3 to 4 months. Palliative systemic chemotherapy is currently the only treatment available in the Netherlands. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has an...

Cite
van der Kaaij RT, Braam HJ, Boot H, et al. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR Res Protoc. 2017;6(7):e136doi: 10.2196/resprot.7790.
van der Kaaij, R. T., Braam, H. J., Boot, H., Los, M., Cats, A., Grootscholten, C., Schellens, J. H., Aalbers, A. G., Huitema, A. D., Knibbe, C. A., Boerma, D., Wiezer, M. J., van Ramshorst, B., & van Sandick, J. W. (2017). Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR research protocols, 6(7), e136. https://doi.org/10.2196/resprot.7790
van der Kaaij, Rosa T, et al. "Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study." JMIR research protocols vol. 6,7 (2017): e136. doi: https://doi.org/10.2196/resprot.7790
van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR Res Protoc. 2017 Jul 13;6(7):e136. doi: 10.2196/resprot.7790. PMID: 28705789; PMCID: PMC5532515.
Copy Download .nbib Format: NLM
Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW.
PMID: 33495964
Gastric Cancer. 2021 Jul;24(4):800-809. doi: 10.1007/s10120-021-01160-1. Epub 2021 Jan 25.

INTRODUCTION: The peritoneum is a predilection site for gastric cancer metastases. Current standard treatment for gastric cancer patients with synchronous peritoneal metastases is palliative systemic therapy. However, its efficacy is largely unknown. The aim of this study was to...

Cite
Koemans WJ, Lurvink RJ, Grootscholten C, et al. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24(4):800-809doi: 10.1007/s10120-021-01160-1.
Koemans, W. J., Lurvink, R. J., Grootscholten, C., Verhoeven, R. H. A., de Hingh, I. H., & van Sandick, J. W. (2021). Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24(4), 800-809. https://doi.org/10.1007/s10120-021-01160-1
Koemans, Willem J, et al. "Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort." Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association vol. 24,4 (2021): 800-809. doi: https://doi.org/10.1007/s10120-021-01160-1
Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021 Jul;24(4):800-809. doi: 10.1007/s10120-021-01160-1. Epub 2021 Jan 25. PMID: 33495964.
Copy Download .nbib Format: NLM
Motion-compensated FDG PET/CT for oesophageal cancer.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Voncken FEM, Vegt E, van Sandick JW, van Dieren JM, Grootscholten C, Bartels-Rutten A, Takken SL, Sonke JJ, van de Kamer JB, Aleman BMP.
PMID: 33825916
Strahlenther Onkol. 2021 Sep;197(9):791-801. doi: 10.1007/s00066-021-01761-w. Epub 2021 Apr 07.

PURPOSE: Respiratory-induced motion of oesophageal tumours and lymph nodes can influence positron-emission tomography/computed tomography (PET/CT). The aim was to compare standard three-dimensional (3D) and motion-compensated PET/CT regarding standardized uptake value (SUV), metabolic tumour volume (MTV) and detection of lymph...

Cite
Voncken FEM, Vegt E, van Sandick JW, et al. Motion-compensated FDG PET/CT for oesophageal cancer. Strahlenther Onkol. 2021;197(9):791-801doi: 10.1007/s00066-021-01761-w.
Voncken, F. E. M., Vegt, E., van Sandick, J. W., van Dieren, J. M., Grootscholten, C., Bartels-Rutten, A., Takken, S. L., Sonke, J. J., van de Kamer, J. B., & Aleman, B. M. P. (2021). Motion-compensated FDG PET/CT for oesophageal cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 197(9), 791-801. https://doi.org/10.1007/s00066-021-01761-w
Voncken, Francine E M, et al. "Motion-compensated FDG PET/CT for oesophageal cancer." Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] vol. 197,9 (2021): 791-801. doi: https://doi.org/10.1007/s00066-021-01761-w
Voncken FEM, Vegt E, van Sandick JW, van Dieren JM, Grootscholten C, Bartels-Rutten A, Takken SL, Sonke JJ, van de Kamer JB, Aleman BMP. Motion-compensated FDG PET/CT for oesophageal cancer. Strahlenther Onkol. 2021 Sep;197(9):791-801. doi: 10.1007/s00066-021-01761-w. Epub 2021 Apr 07. PMID: 33825916.
Copy Download .nbib Format: NLM
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX.

Cancers

Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM.
PMID: 33671266
Cancers (Basel). 2021 Feb 17;13(4). doi: 10.3390/cancers13040839.

We assessed the feasibility of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy. Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m

Cite
Stroes CI, Schokker S, Molenaar RJ, et al. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers (Basel). 2021;13(4)doi: 10.3390/cancers13040839.
Stroes, C. I., Schokker, S., Molenaar, R. J., Mathôt, R. A. A., Bijlsma, M. F., van der Woude, S. O., Belo Pereira, J. P., Hooijer, G. K. J., Verhoeven, R. H. A., Cats, A., Grootscholten, C., van Sandick, J. W., Creemers, G. J., Nieuwenhuijzen, G. A. P., Haj Mohammad, N., Ruurda, J. P., Meijer, S. L., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., & van Laarhoven, H. W. M. (2021). A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 13(4), . https://doi.org/10.3390/cancers13040839
Stroes, Charlotte I, et al. "A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX." Cancers vol. 13,4 (2021). doi: https://doi.org/10.3390/cancers13040839
Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers (Basel). 2021 Feb 17;13(4). doi: 10.3390/cancers13040839. PMID: 33671266; PMCID: PMC7922275.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries